Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting system

BACKGROUND: Immune checkpoint inhibitors (ICIs) and bevacizumab-based therapy are a promising treatment approach to significantly improving overall survival (OS) of non-small cell lung cancer (NSCLC) patients. However, the incidence of adverse events induced by a combination treatment with programme...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Shuai, Tian, Tiantian, Pacheco, Jose M., Tachihara, Motoko, Hu, Pingping, Zhang, Jiandong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264309/
https://www.ncbi.nlm.nih.gov/pubmed/34295666
http://dx.doi.org/10.21037/tlcr-21-464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264309/
https://www.ncbi.nlm.nih.gov/pubmed/34295666
http://dx.doi.org/10.21037/tlcr-21-464

Ejemplares similares